Another quarter is in the books, and not all that much has changed at healthcare giant Johnson & Johnson (NYSE:JNJ).
The company's drug business continues to grow exceptionally well,
lifting margins along the way. Meanwhile, the recovery in the consumer
business continues to be slow, as is the progress in producing better
growth from the large device business. Although I've been lukewarm on
JNJ's shares relative to other (better-performing) stocks in the drug
and device space, the shares have done pretty well over the past year
and while not cheap, aren't all that expensive for long-term holders.
Please read more here:
http://www.investopedia.com/stock-analysis/071713/drugs-driving-jnj-slow-progress-devices-and-consumer-jnj-pfe-mdt-syk.aspx
No comments:
Post a Comment